By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.) 

9620 Medical Center Drive

Rockville  Maryland  20850  U.S.A.
Phone: 240-864-2600 Fax: 301-315-2437


CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing CANCER and other unmet medical needs for the global market, with a focus on China and the U.S.




CEO: Ken Ren

CMO (Medical): Rong Chen


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: CASI Pharma
Employees: 56 employees
Symbol: CASI

Company News
CASI Pharma (CASI) Reports On Enrollment Status Of ENMD-2076 Phase II Study In Triple-Negative Breast Cancer 4/14/2017 7:41:25 AM
CASI Pharma (CASI) Reports 2016 Fourth Quarter And Full Year Financial Results 3/31/2017 9:10:16 AM
CASI Pharma (CASI) Announces Poster Presentations At AACR Annual Meeting 3/28/2017 12:28:20 PM
CASI Pharma (CASI)' Import Drug Registration Application For EVOMELA Accepted For Review By CFDA 12/5/2016 10:44:16 AM
CASI Pharma (CASI) Reports Third Quarter 2016 Financial Results 11/14/2016 11:26:16 AM
CASI Pharma (CASI) Met Endpoint in Phase II ENMD-2076 in Fibrolamellar Carcinoma 8/16/2016 6:34:55 AM
CASI Pharmaceuticals  (CASI) Reports Second Quarter 2016 Financial Results 8/15/2016 9:23:21 AM
ASCO2016: CASI Pharmaceuticals  (CASI) Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC) 6/1/2016 11:26:25 AM
CASI Pharmaceuticals  (CASI) Reports First Quarter 2016 Financial Results 5/13/2016 7:44:33 AM
CASI Pharmaceuticals  (CASI) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 5/12/2016 10:01:35 AM